• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

priority review voucher

accelerated
Biotech

Regeneron, Sanofi receive 1- to 2-month priority review vouchers

The national priority vouchers position companies including Merck KGaA, Regeneron and Sanofi to complete the review process in one to two months.
Nick Paul Taylor Oct 17, 2025 8:30am
Man hands gold dollar sign to another man
Favicon Fierce Pharma

Bavarian Nordic's $160M PRV price reflects new realities

Jun 18, 2025 11:47am
Clock in front of the subway

FDA 'on track' to meet all PDUFA dates, Marty Makary says

Jun 18, 2025 4:00am
Magnifying glass with pills on blue

FDA debuts priority review voucher with 2-month timeline goal

Jun 17, 2025 11:59am
rare diseases

Stealth CEO questions FDA rejection of rare disease drug

May 29, 2025 2:27pm
Money in the hands of businessmen with contract signing

PTC sells priority review voucher from Kebilidi nod for $150M

Nov 27, 2024 8:35am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings